Publications
683 results found
Benjafield AV, Woehrle H, Vettorazzi E, et al., 2022, NEW TREATMENTS FOR CENTRAL SLEEP APNOEA IN HEART FAILURE: SAMPLE SIZE REQUIRED TO DETECT A SAFETY SIGNAL, Publisher: ELSEVIER, Pages: S259-S260, ISSN: 1389-9457
Bottle A, Newson R, Faitna P, et al., 2022, Risk prediction of mortality for patients with heart failure in England: observational study in primary care, ESC HEART FAILURE, ISSN: 2055-5822
Posada-Martinez EL, Cox ZL, Cano-Nieto MM, et al., 2022, Changes in the Inferior Vena Cava Are More Sensitive Than Venous Pressure During Fluid Removal: A Proof-of-Concept Study., J Card Fail
BACKGROUND: Congestion is central to the pathophysiology of heart failure (HF); thus, tracking congestion is crucial for the management of patients with HF. In this study we aimed to compare changes in inferior vena cava diameter (IVCD) with venous pressure following manipulation of volume status during ultrafiltration in patients with cardiac dysfunction. METHODS AND RESULTS: Patients with stable hemodialysis and with systolic or diastolic dysfunction were studied. Central venous pressure (CVP) and peripheral venous pressure (PVP) were measured before and after hemodialysis. IVCD and PVP were measured simultaneously just before dialysis, 3 times during dialysis and immediately after dialysis. Changes in IVCD and PVP were compared at each timepoint with ultrafiltration volumes. We analyzed 30 hemodialysis sessions from 20 patients. PVP was validated as a surrogate for CVP. Mean ultrafiltration volume was 2102 ± 667 mL. IVCD discriminated better ultrafiltration volumes ≤ 500 mL or ≤ 750 mL than PVP (AUC 0.80 vs 0.62, and 0.80 vs 0.56, respectively; both P< 0.01). IVCD appeared to track better ultrafiltration volume (P< 0.01) and hemoconcentration (P< 0.05) than PVP. Changes in IVCD were of greater magnitude than those of PVP (average change from predialysis: -58 ± 30% vs -28 ± 21%; P< 0.001). CONCLUSIONS: In patients undergoing ultrafiltration, changes in IVCD tracked changes in volume status better than venous pressure.
Kotecha D, Asselbergs FW, Achenbach S, et al., 2022, CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research, European Heart Journal, Vol: 43, Pages: 3578-3588, ISSN: 0195-668X
Big data is central to new developments in global clinical science aiming to improve the lives of patients. Technological advances have led to the routine use of structured electronic healthcare records with the potential to address key gaps in clinical evidence. The covid-19 pandemic has demonstrated the potential of big data and related analytics, but also important pitfalls. Verification, validation, and data privacy, as well as the social mandate to undertake research are key challenges. The European Society of Cardiology and the BigData@Heart consortium have brought together a range of international stakeholders, including patient representatives, clinicians, scientists, regulators, journal editors and industry. We propose the CODE-EHR Minimum Standards Framework as a means to improve the design of studies, enhance transparency and develop a roadmap towards more robust and effective utilisation of healthcare data for research purposes.
Kotecha D, Asselbergs FW, Achenbach S, et al., 2022, CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research, LANCET DIGITAL HEALTH, Vol: 4, Pages: E757-E764
Williams K, Modi RN, Dymond A, et al., 2022, Cluster randomised controlled trial of screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the pilot study for the SAFER trial, BMJ OPEN, Vol: 12, ISSN: 2044-6055
Kotecha D, Asselbergs FW, Achenbach S, et al., 2022, CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research, BMJ-BRITISH MEDICAL JOURNAL, Vol: 378, ISSN: 0959-535X
- Author Web Link
- Cite
- Citations: 3
Cowie MR, Bozkurt B, Butler J, et al., 2022, How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?, INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol: 365, Pages: 61-68, ISSN: 0167-5273
Hernandez AF, Albert NM, Allen LA, et al., 2022, Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure, JOURNAL OF CARDIAC FAILURE, Vol: 28, Pages: 1245-1254, ISSN: 1071-9164
- Author Web Link
- Cite
- Citations: 2
Amirova A, Lucas R, Cowie MR, et al., 2022, Perceived barriers and enablers influencing physical activity in heart failure: A qualitative one-to-one interview study, PLOS ONE, Vol: 17, ISSN: 1932-6203
- Author Web Link
- Cite
- Citations: 1
Baumert M, Cowie MR, Redline S, et al., 2022, Sleep characterization with smart wearable devices: a call for standardization and consensus recommendations, SLEEP, Vol: 45, ISSN: 0161-8105
- Author Web Link
- Cite
- Citations: 2
McBeath K, Cowie MR, 2022, Heart failure: classification and pathophysiology, Medicine (United Kingdom), Vol: 50, Pages: 471-478, ISSN: 1357-3039
Heart failure (HF) is a clinical syndrome in which there are characteristic signs and symptoms (e.g. oedema, breathlessness, fatigue) resulting from an underlying abnormality of cardiac function. Understanding the cause of the cardiac dysfunction and the body's response to it is essential in effective management. HF can present acutely, for example as a consequence of an acute myocardial infarction, or in a chronic form in which acute decompensation can then occur. HF results in a plethora of changes in the heart, at the cellular, microscopic and macroscopic levels, with the heart remodelling in response to these abnormal conditions. The underlying cardiac dysfunction also triggers the activation of an array of neuro-hormonal compensatory mechanisms that ultimately become deleterious to cardiac and other organ function; these include sodium and fluid retention, increased sympathetic tone, altered breathing patterns, arrhythmia and, in more advanced stages, an inflammatory state with immune activation.
Tamisier R, Pepin J-L, Cowie MR, et al., 2022, Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE-HF major sub study, JOURNAL OF SLEEP RESEARCH, Vol: 31, ISSN: 0962-1105
Cowie MR, Mourilhe-Rocha R, Chang H-Y, et al., 2022, The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network, INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol: 363, Pages: 240-246, ISSN: 0167-5273
- Author Web Link
- Cite
- Citations: 1
Guasti L, Dilaveris P, Mamas MA, et al., 2022, Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Geriatric Cardiology, the ESC Digital Health Committee and the ESC Working Group on e-Cardiology, ESC HEART FAILURE, Vol: 9, Pages: 2808-2822, ISSN: 2055-5822
- Author Web Link
- Cite
- Citations: 2
Jankowska EA, Liu P, Cowie MR, et al., 2022, Personalized care of patients with heart failure - REWOLUTION HF international survey on cardiologists' educational needs, Publisher: WILEY, Pages: 119-120, ISSN: 1388-9842
Jankowska EA, Liu P, Cowie MR, et al., 2022, Personalized care of patients with heart failure - REWOLUTION HF international survey on patients' needs and perceptions, Publisher: WILEY, Pages: 137-137, ISSN: 1388-9842
Rayman G, Akpan A, Cowie M, et al., 2022, Managing patients with comorbidities: future models of care., Future Healthc J, Vol: 9, Pages: 101-105, ISSN: 2514-6645
One in four adults in the UK have two or more medical conditions. One in three adults admitted to hospital in the UK have five or more conditions. People with multimorbidity have poorer functional status, quality of life and health outcomes, and are higher users of ambulatory and inpatient care than those without multimorbidity. The entire healthcare system needs to change so that it can provide a better service for patients with multimorbidity. The system of healthcare professional education needs to change also. Clinical decision support has a clear role in the management of patients with multimorbidity. But, until now, clinical decision support tools have offered no support when dealing with patients with comorbidities; they have covered single conditions only. In light of this, BMJ Best Practice recently launched the Comorbidities Manager. This enables healthcare professionals to add a patient's comorbidities to an existing management plan and get a tailored plan instantly. This article outlines the importance of taking into account comorbidities when managing patients and the role that the BMJ Comorbidities Manager can play in this regard.
Fisser C, Gall L, Bureck J, et al., 2022, Effects of Adaptive Servo-Ventilation on Nocturnal Ventricular Arrhythmia in Heart Failure Patients With Reduced Ejection Fraction and Central Sleep Apnea-An Analysis From the SERVE-HF Major Substudy, FRONTIERS IN CARDIOVASCULAR MEDICINE, Vol: 9, ISSN: 2297-055X
Butler J, Stebbins A, Melenovsky V, et al., 2022, Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial, CIRCULATION-HEART FAILURE, Vol: 15, ISSN: 1941-3289
- Author Web Link
- Cite
- Citations: 1
Leclercq C, Witt H, Hindricks G, et al., 2022, Wearables, telemedicine, and artificial intelligence in arrhythmias and heart failure: Proceedings of the European Society of Cardiology: Cardiovascular Round Table, EUROPACE, ISSN: 1099-5129
- Author Web Link
- Cite
- Citations: 5
Fox KAA, Aboyans V, Debus ES, et al., 2022, Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry, EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, Vol: 8, Pages: 825-836, ISSN: 2055-6837
- Author Web Link
- Cite
- Citations: 4
Cowie MR, Cleland JGF, 2022, The COVID-19 pandemic and heart failure: lessons from GUIDE-HF, EUROPEAN HEART JOURNAL, Vol: 43, Pages: 2619-2621, ISSN: 0195-668X
- Author Web Link
- Cite
- Citations: 2
Levy P, Naughton MT, Tamisier R, et al., 2022, Sleep apnoea and heart failure, EUROPEAN RESPIRATORY JOURNAL, Vol: 59, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 3
McBeath KCC, Angermann CE, Cowie MR, 2022, Digital Technologies to Support Better Outcome and Experience of Care in Patients with Heart Failure, CURRENT HEART FAILURE REPORTS, Vol: 19, Pages: 75-108, ISSN: 1546-9530
- Author Web Link
- Cite
- Citations: 2
Konstam MA, Mann DL, Udelson JJE, et al., 2022, Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure, FRONTIERS IN PHYSIOLOGY, Vol: 13
Cowie MR, McBeath KCC, Angermann CE, 2022, The Digital Future of Heart Failure Care, CURRENT HEART FAILURE REPORTS, Vol: 19, Pages: 109-113, ISSN: 1546-9530
Bottle R, Newson R, Faitna P, et al., 2022, Changes in heart failure management and long-term mortality over ten years: observational study, Open Heart, Vol: 9, ISSN: 2053-3624
Objectives: To estimate the long-term survival of two cohorts of people diagnosed with heart failure 10 years apart and to assess differences in patient characteristics, clinical guideline compliance and survival by diagnosis setting.Methods Data: for patients aged 18 and over with a new diagnosis of heart failure in the Clinical Practice Research Datalink in 2001–2002 (5966 patients in 156 practices) and 2011–2012 (12 827 patients in 331 practices). Survival rates since diagnosis were described using Kaplan-Meier plots. Compliance with national guidelines was summarised.Results: 2011/2012 patients were older than those diagnosed a decade before, with lower blood pressure and cholesterol but more comorbidity and healthcare contacts. For those diagnosed in 2001/2002, the 5-year survival was 40.0% (40.2% in the 2011/2012 cohort), 10-year survival was 20.8%, and 15-year survival 11.1%. Improvement in survival between the two time periods was seen only in those diagnosed in primary care (5-year survival 46.0% vs 57.4%, compared with 33.9% and 32.6% for hospital-diagnosed patients).Beta-blocker use rose from 24.3% to 39.1%; renin–angiotensin system blockers rose from 31.8% to 54.3% (both p<0.001). There was little change for loop diuretics and none for thiazide diuretics. For the 9963 patients with symptoms recorded by their general practitioner before diagnosis, brain natriuretic peptide (BNP) testing was low, but echocardiogram use rose from 8.3% to 19.3%, and specialist referral rose from 7.2% to 24.6% (all p<0.001).
Kouranos V, Khattar RS, Ahmed R, et al., 2022, MODE OF PRESENTATION, PROGNOSIS AND PREDICTORS OF OUTCOME IN A CONTEMPORARY CARDIAC SARCOIDOSIS POPULATION, Publisher: ELSEVIER SCIENCE INC, Pages: 553-553, ISSN: 0735-1097
Halliday B, Owen R, Gregson J, et al., 2022, Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy, ESC Heart Failure, Vol: 9, ISSN: 2055-5822
Aims: To profile the changes in non-invasive clinical, biochemical and imaging markers during withdrawal of therapy in patients with recovered dilated cardiomyopathy, providing insights into the pathophysiology of relapse.Methods: Clinical, biochemical and imaging data from patients during phased withdrawal of therapy in the randomised or single-arm cross-over phases of TRED-HF were profiled. Clinical variables were measured at each study visit and imaging variables were measured at baseline, 16 weeks and 6 months. Results: Amongst the 49 patients (35% women, mean age 53.6 years [standard deviation 11.6]) who withdrew therapy, 20 relapsed. Increases in mean heart rate (7.6 beats per minute [95% CIs 4.5,10.7]), systolic blood pressure (6.6mmHg [95% CI 2.7,10.5]) and diastolic blood pressure (5.8mmHg [95% CI 3.1,8.5]) were observed within 4-8 weeks of starting to withdraw therapy. A rise in mean LV mass (5.1g/m2 [95%CI 2.8,7.3]) and LV end-diastolic volume (3.9ml/m2 [95% CI 1.1,6.7]) and a reduction in mean LV ejection fraction (-4.2 [95% CI -6.6, -1.8]) were seen by 16 weeks, the earliest imaging follow-up. Plasma NT-pro-BNP fell immediately after withdrawing beta-blockers and only tended to increase 6 months after beginning therapy withdrawal (mean change in log NT-pro-BNP at 6 months: 0.2, 95% CI -0.1,0.4). Conclusion: Changes in plasma NT-pro-BNP are a late feature of relapse, often months after a reduction in LV function. A rise in heart rate and blood pressure are observed soon after withdrawing therapy in recovered dilated cardiomyopathy, typically accompanied or closely followed by early changes in LV structure and function.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.